Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3016463 | 0.81 | KMT2A (0.64) | ATMKMT2ATSHRHSD17B10ALDH1A1 | |
| SCHEMBL17298915 | 0.78 | HDAC4 (0.47) | KMT2AHDAC6MAPTARHDAC4 | |
| SCHEMBL6823997 | 0.70 | EPHX2 (0.33) | HDAC6EPHX2 | |
| SCHEMBL16081991 | 0.70 | PKM (0.37) | HDAC6ALDH1A1L3MBTL1EPHX2HPGD | |
| SCHEMBL5806478 | 0.68 | KMT2A (0.67) | ATMKMT2ATSHRHSD17B10ALDH1A1 | |
| SCHEMBL13091637 | 0.67 | ATM (0.47) | ATMKMT2ATSHRHSD17B10ALDH1A1 | |
| SCHEMBL30962423 | 0.67 | CYP1A2 (0.36) | HDAC6EPHX2 | |
| SCHEMBL18010971 | 0.66 | CTSK (0.44) | ATMKMT2AALDH1A1HPGD | |
| SCHEMBL24040866 | 0.66 | HDAC4 (0.47) | KMT2AHDAC6ALDH1A1HDAC4 | |
| SCHEMBL24754781 | 0.66 | ALDH1A1 (0.46) | KMT2ATSHRALDH1A1MAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-10300067-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-28 | — | — | US | disclosed |
| EP-3150599-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-10-24 | — | — | EP | disclosed |
| US-20180161331-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9889136-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9662333-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-3150599-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-04-05 | — | — | EP | disclosed |
| US-20160310496-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160244444-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161331-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | NR5A1, CYP17A1, AR | ATM 2122/4885KMT2A 1136/4885TSHR 3100/4885 |
| US-10300067-B2 | Tetrahydropyridopyrimidine compound or salt thereof | NR5A1, CYP17A1, DPYD | ATM 1955/4885KMT2A 1083/4885TSHR 3183/4885 |
| US-20160310496-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | NR5A1, CYP17A1, AR | ATM 2122/4885KMT2A 1136/4885TSHR 3100/4885 |
| US-20160244444-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | AR, NR5A1, NR5A2 | ATM 1603/4885KMT2A 1268/4885TSHR 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.